Phospholipase A2 activation coupled to lipoxygenase and cyclooxygenase pathways in the guinea pig myometrium: interaction with the cyclic AMP and cyclic GMP systems.
D000818:Animals; D000001:Calcimycin / Q000494:pharmacology; D002217:Carbachol / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism*; D006152:Cyclic GMP / Q000378:metabolism*; D004789:Enzyme Activation; D011464:Epoprostenol / Q000096:biosynthesis; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology; D005260:Female; D006168:Guinea Pigs; D008084:Lipoxygenase / Q000378:metabolism*; D009215:Myometrium / Q000187:drug effects / Q000201:enzymology*; D010740:Phospholipases / Q000378:metabolism*; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D014599:Uterus / Q000201:enzymology*
D005231:Fatty Acids, Unsaturated; D000001:Calcimycin; D002217:Carbachol; D011464:Epoprostenol; D000242:Cyclic AMP; D008084:Lipoxygenase; D011451:Prostaglandin-Endoperoxide Synthases; D010740:Phospholipases; D010741:Phospholipases A; D054467:Phospholipases A2; D006152:Cyclic GMP